Study Summary
This trial will explore whether a new imaging scan can predict how well a patient with renal cell carcinoma will respond to immunotherapy.
- Kidney Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: Up to 5 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Cohort 1
1 of 2
Cohort 2
1 of 2
Experimental Treatment
40 Total Participants · 2 Treatment Groups
Primary Treatment: 89Zr-DFO-Atezolizumab · No Placebo Group · Phase < 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Mulgaonkar, Aditi, Roy Elias, Layton Woolford, Bing Guan, Kien Nham, Payal Kapur, Alana Christie, et al.. 2022. “Immunopet Imaging with 89zr-labeled Atezolizumab Enables in Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma”. Clinical Cancer Research. American Association for Cancer Research (AACR). doi:10.1158/1078-0432.ccr-22-1547.
- Mulgaonkar A, Elias R, Woolford L, Guan B, Nham K, Kapur P, Christie A, Tcheuyap VT, Singla N, Bowman IA, Stevens C, Hao G, Brugarolas J, Sun X. ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma. Clin Cancer Res. 2022 Nov 14;28(22):4907-4916. doi: 10.1158/1078-0432.CCR-22-1547.
- James Brugarolas 2019. "89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04006522.
Frequently Asked Questions
What medical condition is 89Zr-DFO-Atezolizumab typically employed to address?
"89Zr-DFO-Atezolizumab has been demonstrated to be efficacious in the treatment of small cell lung cancer (sclc), malignant neoplasms, and non-small cell lung carcinoma." - Anonymous Online Contributor
To what extent is participation in this clinical trial being observed?
"Indeed, clinicaltrials.gov verifies that this medical study is in the process of recruiting participants. It was first posted on October 2nd 2019 and its most recent update occurred on August 2nd 2022. 40 patients are needed to complete enrollment at a single centre." - Anonymous Online Contributor
Is this the inaugural iteration of this clinical experiment?
"Research into 89Zr-DFO-Atezolizumab began in 2008 with a clinical trial funded by Hoffmann La Roche. After positive outcomes from the first study of 720, this drug was granted Phase 2 approval and is now being evaluated in 348 studies located across 74 different nations." - Anonymous Online Contributor
Are individuals currently being accepted to participate in this research?
"According to clinicaltrials.gov, this medical study is currently in recruitment mode. It was initially posted on October 2nd 2019 and the last update came on August 2nd 2022." - Anonymous Online Contributor